Predictive value of thyroid-stimulating hormone in postmenopausal type 2 diabetes mellitus patients with normal thyroid function associated with ultrasound-diagnosed non-alcoholic fatty liver disease

References

• Al Humayed SM, Sabaani A, Mahfouz AA, Awadalla NJ, Musa MJ, Patel A. 2020. Clinical and biochemical predictors of nonalcoholic fatty liver disease among Type 2 diabetes mellitus patients at primary health care level in south western Saudi arabia. Diagnostics. 10:809.
   Web of Science ®Google Scholar
• American Diabetes A. 2010. Diagnosis and classification of diabetes mellitus. Diab Care. 33(Suppl 1):S62–S69.
   PubMed Web of Science ®Google Scholar
• Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, Park CY, Oh KW, Sung KC, Kim BI. 2010. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol. 105:2389–2395.
   PubMed Web of Science ®Google Scholar
• Borai IH, Shaker Y, Kamal MM, Ezzat WM, Ashour E, Afify M, Gouda W, Elbrashy MM. 2017. Evaluation of biomarkers in Egyptian patients with different grades of nonalcoholic fatty liver disease. J Clin Transl Hepatol. 5:109–118.
   PubMed Web of Science ®Google Scholar
• Castera L, Friedrich-Rust M, Loomba R. 2019. Noninvasive assessment of liver disease in patients With nonalcoholic fatty liver disease. Gastroenterology. 156:1264–1281.e1264.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhu Z, Mao Y, Xu Y, Du J, Tang X, Cao H. 2020. Hba1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels. Biosci Rep. 40:BSR20193996.
   Web of Science ®Google Scholar
• Chen CX, Du J, Xu YM, Han JX, Zhu ZW, Mao YS, Guo CY. 2018. [Predictive value of serum glycosylated hemoglobin for the onset of nonalcoholic fatty liver disease]. Zhonghua gan Zang Bing za zhi. 26:765–770.
   PubMedGoogle Scholar
• Dai H, Wang W, Chen R, Chen Z, Lu Y, Yuan H. 2017. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond). 14:49.
   PubMed Web of Science ®Google Scholar
• De Roza MA, Goh GB. 2019. The increasing clinical burden of NAFLD in Asia. Lancet Gastroenterol Hepatol. 4:333–334.
   PubMed Web of Science ®Google Scholar
• Fan JG, Wei L, Zhuang H. 2019. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). J Dig Dis. 20:163–173.
   PubMed Web of Science ®Google Scholar
• Farthing M, Albonico M, Bisoffi Z, Bundy D, Buonfrate D, Chiodini P, Katelaris P, Kelly P, Savioli L, Mair AL. 2020. World gastroenterology organisation global guidelines: management of strongyloidiasis February 2018-compact version. J Clin Gastroenterol. 54:747–757.
   PubMed Web of Science ®Google Scholar
• Fierbinteanu-Braticevici C, Baicus C, Tribus L, Papacocea R. 2011. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). J Gastrointest Liver Diseases: JGLD. 20:153–159.
   PubMed Web of Science ®Google Scholar
• Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H, Takahashi H, Hara T, Tanaka S, Sumida Y, Japan Study Group of Nonalcoholic Fatty Liver D, et al. 2019. HOMA-IR: an independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 34:1390–1395.
   PubMed Web of Science ®Google Scholar
• Gokmen FY, Ahbab S, Ataoglu HE, Turker BC, Cetin F, Turker F, Mamac RY, Yenigun M. 2016. FT3/FT4 ratio predicts non-alcoholic fatty liver disease independent of metabolic parameters in patients with euthyroidism and hypothyroidism. Clinics. 71:221–225.
   PubMed Web of Science ®Google Scholar
• Gu Y, Wu X, Zhang Q, Liu L, Meng G, Wu H, Zhang S, Wang Y, Zhang T, Wang X, et al. 2022. High-normal thyroid function predicts incident non-alcoholic fatty liver disease among middle-aged and elderly euthyroid subjects. J Gerontol A Biol Sci Med Sci. 77:197–203.
   Web of Science ®Google Scholar
• Hattori N, Ishihara T, Yamagami K, Shimatsu A. 2015. Macro TSH in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf). 83:923–930.
   PubMed Web of Science ®Google Scholar
• Hu DS, Zhu SH, Liu WY, Pan XY, Zhu PW, Li YY, Zheng KI, Ma HL, You J, Targher G, et al. 2020. PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. Diabetes Metab. 46:496–503.
   PubMed Web of Science ®Google Scholar
• Kim D, Kim W, Joo SK, Bae JM, Kim JH, Ahmed A. 2018. Subclinical hypothyroidism and Low-normal thyroid function Are associated with nonalcoholic steatohepatitis and fibrosis. Clin Gastroenterol Hepatol: The Off Clin Pract J Am Gastroenterol Assoc. 16:123–131.e121.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang W, Yu X, Qi X. 2018. Thyroid function and risk of non-alcoholic fatty liver disease in euthyroid subjects. Ann Hepatol. 17:779–788.
   PubMed Web of Science ®Google Scholar
• Ma H, Xu C, Xu L, Yu C, Miao M, Li Y. 2013. Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population. BMC Gastroenterol. 13:3.
   PubMed Web of Science ®Google Scholar
• Maratou E, Hadjidakis DJ, Peppa M, Alevizaki M, Tsegka K, Lambadiari V, Mitrou P, Boutati E, Kollias A, Economopoulos T, et al. 2010. Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism. Eur J Endocrinol. 163:625–630.
   PubMed Web of Science ®Google Scholar
• Mcpherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, et al. 2017. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 112:740–751.
   PubMed Web of Science ®Google Scholar
• Setroame AM, Kormla Affrim P, Abaka-Yawson A, Kwadzokpui PK, Eyram Adrah F, Bless H, Mohammed L, Bawah AT, Alidu HW. 2020. Prevalence of metabolic syndrome and nonalcoholic fatty liver disease among premenopausal and postmenopausal women in Ho municipality: a cross-sectional study. BioMed Res Int. 2020:2168381.
   PubMed Web of Science ®Google Scholar
• Sinha RA, Singh BK, Yen PM. 2018. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol. 14:259–269.
   PubMed Web of Science ®Google Scholar
• Soleimani D, Paknahad Z, Rouhani MH. 2020. Therapeutic effects of garlic on hepatic steatosis in nonalcoholic fatty liver disease patients: a randomized clinical trial. Diabetes Metab Syndr Obes. 13:2389–2397.
   PubMed Web of Science ®Google Scholar
• Tada T, Toyoda H, Sone Y, Yasuda S, Miyake N, Kumada T, Tanaka J. 2019. Type 2 diabetes mellitus: a risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 34:2011–2018.
   PubMed Web of Science ®Google Scholar
• Tahara K, Akahane T, Namisaki T, Moriya K, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Sato S, et al. 2020. Thyroid-stimulating hormone is an independent risk factor of non-alcoholic fatty liver disease. JGH Open: An Open Access Journal of Gastroenterology and Hepatology. 4:400–404.
   PubMed Web of Science ®Google Scholar
• Tao Y, Gu H, Wu J, Sui J. 2015. Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid subjects. Endocr Res. 40:74–78.
   PubMed Web of Science ®Google Scholar
• Tuong TTK, Tran DK, Phu PQT, Hong TND, Dinh TC, Chu DT. 2020. Non-alcoholic fatty liver disease in patients with Type 2 diabetes: evaluation of hepatic fibrosis and Steatosis using fibroscan. Diagnostics. 10:159.
   Web of Science ®Google Scholar
• Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR. 2020. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology. 71:907–916.
   PubMed Web of Science ®Google Scholar
• Zhang JZ, Cai JJ, Yu Y, She ZG, Li H. 2019. Nonalcoholic fatty liver disease: an update on the diagnosis. Gene Expr. 19:187–198.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shi R, Yu L, Ji L, Li M, Hu F. 2020. Establishment of a risk prediction model for non-alcoholic fatty liver disease in Type 2 diabetes. Diabetes Therapy: Res, Treat Educ Diabetes Relat Disord. 11:2057–2073.
   Google Scholar